Commission Implementing Regulation (EU) No 466/2012
of 1 June 2012
amending the Annex to Regulation (EU) No 37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin, as regards the substance clorsulon
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,
Whereas:
The maximum residue limit (MRL) for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry should be established in accordance with Regulation (EC) No 470/2009.
Clorsulon is currently included in Table 1 of the Annex to Regulation (EU) No 37/2010 as an allowed substance, for bovine species, applicable to muscle, liver and kidney, excluding animals producing milk for human consumption.
Ireland has submitted to the European Medicines Agency a request for an opinion for the extrapolation of the existing entry for clorsulon applicable to bovine milk.
The Committee for Medicinal Products for Veterinary Use (CVMP) has recommended the establishment of a provisional MRL for clorsulon for bovine milk and the removal of the provision banning the use of that substance in animals from which milk is produced for human consumption.
The entry for clorsulon in Table 1 of the Annex to Regulation (EU) No 37/2010 should therefore be amended to include the recommended provisional MRL for bovine milk and to remove the existing ban.
The provisional MRL for clorsulon set out in that Table should expire on 1 January 2014. The CVMP recommended a two-year period to allow for the completion of scientific studies required to respond to the list of questions addressed by the CVMP to Ireland.
It is appropriate to provide for a reasonable period of time for the stakeholders concerned to take measures that may be required to comply with the newly set MRL.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
HAS ADOPTED THIS REGULATION: